Loading
A phase 1/2 trial of Fludarabine, Cyclophosphamide in hepatocellular carcinoma, run by Beijing Biotech, now recruiting.
Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC is a phase 1/2 interventional study registered as NCT07500220 by Beijing Biotech, with 30 participants planned, started 2026-03-02 and due to reach its primary completion in 2027-03-14. Interventions recorded: EB-G3B7-NK dual-target CAR-NK cells, Fludarabine, Cyclophosphamide. Conditions listed: Advanced Hepatocellular Carcinoma (HCC), Metastatic Liver Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Shares Advanced hepatocellular carcinoma (BCLC C), Hepatocellular carcinoma.
Shares Fludarabine, Cyclophosphamide.
Shares Fludarabine, Cyclophosphamide.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/